Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613613 · ClinicalTrials.gov registry record
Fenofibrate and Pharmacogenetic Impact in Dyslipidemia
A clinical trial, sponsored by University of Minnesota.
- Completed
- Registry status
- 56
- Enrollment target
NCT00613613: Completed study, sponsored by University of Minnesota.
NCT00613613 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00613613 has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- 56 participants
- Enrollment target
Study Summary
The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body handles the drug) and drug targets (how the drug acts on the body) influences how a person responds to the lipid lowering medication-fenofibrate.
Primary Outcome
We measured area under the curve (AUC) in mcg\*hr/mL (from time 0 to 24 hrs) at steady state for those of two specific genotypes for our UGT2B7 SNP following steady-state dosing of fenofibrate.
Interventions
- DRUG fenofibrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-12 |
What the finished NCT00613613 record still lists
NCT00613613 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 56 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which fenofibrate is the first listed.
NCT00613613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00613613 about?
NCT00613613 is a clinical study titled "Fenofibrate and Pharmacogenetic Impact in Dyslipidemia". The purpose of the study is to learn whether genetics plays a role in predicting response to a commonly used and FDA (Food and Drug Administration) approved medication for lowering triglycerides and cholesterol. The hypothesis: The pharmacogenetics of genes which affect drug metabolism (how the body...
What is the current status of trial NCT00613613?
This trial is currently completed. The enrollment target is 56 participants. The study started on 2008-01. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00613613?
The interventions under investigation include: fenofibrate (DRUG).
Who is sponsoring clinical trial NCT00613613?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia